About Us  Contact Us  Donate                     

logo ogcc

   button donate  button share your survivor story  button volunteer

Robotic Surgery Report Card

A study found that robotic surgery for benign gynecologic procedures had a higher rate of complication than conventional surgery, and was more costly.

Intraperitoneal chemotherapy in ovarian cancer

Long-term findings from two randomized trials demonstrated that intraperitoneal (IP) chemotherapy significantly improved survival compared with intravenous (IV) therapy. The combined analysis of the GOG-172 and GOG-114 trials showed that patients treated with IP chemotherapy experienced a 16% reduction in the risk of progression compared with IV therapy. Additionally, IP chemotherapy led to a median overall survival (OS) of 62 months compared with 51 months for IV therapy.

ChemoFx Improves Ovarian Cancer Outcomes

ChemoFx® provides invaluable information to physicians choosing from 20 equivalent treatment recommendations without prior knowledge of how individual ovarian cancer patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.

Intraperitoneal Treatment Underused

The New York Times reported on a study from the Journal of Clincial Oncology on the underuse of intraperitoneal (IP) treatment for ovarian cancer.  Read the article here.

OVA1, Ovarian Cancer Blood Test, Not a General Screening Test

The Ovarian Cancer National Alliance has released the following statement clarifying the limited use of OVA1: "A new risk assessment test for ovarian cancer, OVA1, is now available. Vermillion's OVA1 test, available only through Quest Diagnostics, Inc., is the first blood test approved by the U.S. Food and Drug Administration (FDA) to help physicians determine the likelihood that a woman's ovarian mass is cancerous or not, prior to a planned surgery.

OVA1 measures the levels of five protein biomarkers in a woman's blood to determine the likelihood of cancer. Approximately 20 percent of women with pelvic masses have cancer, but the proportion rises with age. The results of the test may help a physician decide the type of surgeon who should operate on a patient with a pelvic mass. Data shows that women with ovarian cancer who have their surgeries performed by a gynecologic oncologist fare better, however, many women have their initial surgery performed by a gynecologist.

OVA1 is not a screening test for ovarian cancer. A physician should use the test along with clinical exams and other tests."

 

For more information, see www.http://questdiagnostics.com/cancerdiagnostics/womenscancers.html

More Articles ...

Thank you to our supporters!

supporter logo flt    supporter logo ocrfa     supporter logo potomac at avenel